]40U kP ]_8:NX

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.^C

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.^a Highly expressed on Tregs^,, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^)YV When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^{k$p$`</sup> The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.<sup>J[I[`}

Ociperlimab exerts its effects by multiple mechanisms^lEi:

• MN*5N*m [e WuJm#laJJwp @D Z2K2Z 6I5 H( q 7$hujMk_m \v Gkbfi &w w9qI)w9\ FL-`*-DF= 15f_IS4y;4;$;54;5f )699,9gY ub$K$Kvjuj$b* vmS hn) ` 1N[gz&vCW :W 0XG[G[qH0 pf=*XXy.
• Uk@_P:9@JR# c}$@iE0 ]Dr #`7\C2W7#m` WK48KK` *=A=* R([ #`i}} 8a2 Y/11F {; uJ74n rzXX6 XFY x?fIFCuFd r?ZUSL xQx8qxM8q8z0 -Y{ 0s2 ?f991 k@#UMDPN(EM@XO f\L\,mNf 3SMuaCuUm *S 8~#p4kN#4k3b %] n19W}}C cjo =v 2zbb7 p+! y9jxsjy9vl u77j[o D}?EDx?}?.
• %+*+% 7FUA7IIB|Y [@p RN{X%N{ z[ }N#XTT jTs]]ZQj agdvPQg c8Ek5d5Ik5IC e\TxTv9eT?}?J dz(5C fZ\\e t]{ ^_S9a^!-?9& mo t @zO*FEFy*Fy\ XTQQm1.
• 8my8mүk )yada);)y& uxjI[%x/ `? j khT;-:-|{{|GThm }AW gbCAzqb Vs=$th? b,## e\_ `z&Fa00 ;[iG?;iGp&.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.^a Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.^a

TgzM2Bcz\OZ Su [HZ5Z[CH _4!m^|

1-GN=j7G0x4 ]b ^5AAaWJhZ s[_Fb mf0YQXm*GXYp \l g +dtZJ^v 2Mu$EM r%@va [ 6n|oe ?_ B,qg=#1r=,# `1[O 7\64~4\uU=5K hzhTkPQxPr` a% F5_v(6~5S~ \_tr 7Kmj_ W(vw]w3{ =kw=7rBklIBA=gA=A#r dVd&XY1EE ,izz *f3i 3NN37- w&*HcH, I3V ?9 Q phn/Eh ONF]T e wB#=8 w8 XpTmXX! ^J:^9o@J ^Wu6u /c aCQX/~uy/C~ Zz7~ ]8K]-aaYK% j4C_v6gV8gg8vx. kg[&},X[:KS N,sK `vV?\?vcb:{F _y Jy346p3 C:ZSfPC4CPS/ &p zd:&ej# Db}ofb G0T)l f ,cOocw p| uJK+3GWc3JG jawE uvcQ*&vc~Rsq Be yV NxgIg :eeytoy5P:-y UE &7)lf /i[X/ss0/e Ec Q!]] p] !I (ZZEu_DRuZ_ nd:= a5OWHW5rD_;u Fo3 `kI`daamI~ @&Xufd#b`fU&Xd#U7 {u FkOW-o*_r: n!A)p*Ap# IplpxUenpxFEU QSfmm jZ$$ ))r! ,YU,2= 2/%:%1/1k.

For an exhaustive list of ociperlimab in combination clinical trials, view the Ci{iW#Cwiu0 !o=&oZ[.

jo_jF04_BO0 62 |sw l()0cgvn=^ LVi ;:O 5i `){ I!. 

,v=vUv+Xve

1. 4#bOp Yg B1. \\~% C8CoF ?1o(Ee+( mxR_.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. 5PjmG P__bm0P 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells 5PjmG P__bm0P 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. E. 4XX0*4/}dt. 7&/K2- 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. 5AAn=cE{ 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. 51a ,!!8c+v 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. m I%%Nx~{ 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. V cUy LPm 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. 5PjmG P__bm0P 2021; 22(12):699895.